Trial Profile
A Trial Assessing the Implications of Switching From Insulin Glargine to Insulin Degludec in Subjects With Type 2 Diabetes Mellitus (BEGIN: SIMPLIFY).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Dec 2013
Price :
$35
*
At a glance
- Drugs Insulin degludec (Primary) ; Antihyperglycaemics; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms BEGIN; BEGIN-SIMPLIFY
- Sponsors Novo Nordisk
- 17 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Jul 2010 Planned end date changed from 1 Dec 2010 to 1 Nov 2010 as reported by ClinicalTrials.gov.
- 28 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.